Program
adrixetinib
Also written as “Q702” and “Adrixetinib”.
Its studies are mostly in Esophageal Neoplasms · Neoplasm Metastasis · Bronchiolitis Obliterans Syndrome, led by Qurient.
Furthest: phase 2, since May 20, 20223 company-led studies, 2 open or runningNext primary completion: Dec 30, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Qurient | 32 open or running | phase 2since May 20, 2022 | Nov 19, 2020 | Dec 30, 2027phase 2 · NCT05438420 |
Also a collaborator on its studies: Merck.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 19, 2020First study: phase 1 study in Neoplasm MetastasisFirst studyNCT04648254 · 51 enrolled · United States
- May 20, 2022Phase 2 study in Esophageal NeoplasmsNCT05438420 · 120 enrolled · United States, South Korea
- Aug 11, 2025Phase 1 study in Bronchiolitis Obliterans SyndromeNCT07138196 · 18 planned · Spain
Ahead
- Dec 30, 2027Primary completion: phase 2 study in Esophageal NeoplasmsNCT05438420
- Oct 23, 2029Primary completion: phase 1 study in Bronchiolitis Obliterans SyndromeNCT07138196
TargetBeta
“An orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) Axl (UFO), Mer, and colony stimulating factor-1 receptor (CSF1R; CSF-1R; CD115; M-CSFR), ”NCIt, by rule
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07138196Bronchiolitis Obliterans Syndrome · Spain | 1 | Recruiting | Oct 23, 2029 | 18 |
| NCT05438420Esophageal Neoplasms · United States, South Korea | 2 | Active, not recruiting | Dec 30, 2027 | 120 |
| NCT04648254Neoplasm Metastasis · United States | 1 | Completed | Dec 23, 2025 | 51 |
How it is read
Names in the registry
- “Q702”, 2 entries
- “Adrixetinib”, 1 entry
Conditions, from the studies’ own filings
- Esophageal Neoplasms, 1 study
- Neoplasm Metastasis, 1 study
- Bronchiolitis Obliterans Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.